Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Procalcitonin-guided Antibiotics in AECOPD
NCT04682899Phase 3Unknown
- Sponsor
- Capital Medical University
- Start
- Feb 2021
- Primary completion
- Feb 2022
01
Overview
Phase 3, randomised, open-label trial in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Capital Medical University. Primary endpoints: Antibiotic prescription rate at 30 days and Treatment success rate at 30 days. Status: unknown.
02
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04682899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04682899.